Crossmark

1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

Crossref DOI link: https://doi.org/10.1186/s13014-020-01510-w

Published Online: 2020-03-23

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alongi, Filippo

Rigo, Michele

Figlia, Vanessa

Cuccia, Francesco

Giaj-Levra, Niccolò

Nicosia, Luca

Ricchetti, Francesco

Sicignano, Gianluisa

De Simone, Antonio

Naccarato, Stefania

Ruggieri, Ruggero

Mazzola, Rosario
License Information

Text and Data Mining valid from 2020-03-23

Version of Record valid from 2020-03-23
More Information

Article History

Received: 19 February 2020

Accepted: 9 March 2020

First Online: 23 March 2020

Ethics approval and consent to participate

: All patients signed a informed consent for the treatment.

: yes

: FA acts as Elekta consultant and he had speaker honoraria. The remaining authors declare that they have no competing interests.

Document is current

Any future updates will be listed below